Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)

NCT03639740 is registered in ClinicalTrials.gov with Professor Mikkel Østergaard as lead sponsor.

NCT NCT03639740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)
Lead sponsor
Professor Mikkel Østergaard
Phase
Phase 4
Overall status
Unknown status
Start date
January 15, 2019
Completion date
February 28, 2021
Enrollment
88 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, axial spondyloarthritis